Literature DB >> 10619399

Genomic structure and transcriptional regulation of the human somatostatin receptor type 2.

S Petersenn1, A C Rasch, S Presch, F U Beil, H M Schulte.   

Abstract

Somatostatin exerts inhibitory effects on virtually all endocrine and exocrine secretions. The somatostatin receptor subtype 2 (sst2) acts as a critical molecule for growth hormone regulation and cell proliferation. We investigated the structure and regulation of the human sst2 gene. A genomic clone including the sst2 gene was isolated, 1.5 kb of the promoter was sequenced and putative transcription factor binding sites were identified. The transcription start site was located 93 nucleotides upstream of the translation start site. The nucleotide sequences of the complete gene and 0.5 kb of 3' region were determined. A possible polyadenylation signal was identified. Transcriptional regulation was investigated by transient transfections using various promoter fragments. A -1100 sst2 promoter directed significant levels of luciferase expression in GH4 rat pituitary cells and Skut1-B endometrium cells whereas only low activity was detected in JEG3 chorion carcinoma cells or COS-7 monkey kidney cells. A minimal -252 promoter allowed cell specific expression. We did not find any regulation of the sst2 promoter by somatostatin, forskolin, TRH, TPA, T3, and 17beta-estradiol. Glucocorticoids lead to a significant inhibition of sst2 promoter activity. Further mapping suggest a glucocorticoid-responsive element between -905 and -707 and between -252 and -163. These studies demonstrate the nature of the human sst2 gene and identify its 5' and 3' flanking regions. Furthermore, specific activity of the promoter and regulation by various hormones is demonstrated.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10619399     DOI: 10.1016/s0303-7207(99)00161-6

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  9 in total

Review 1.  Pituitary somatostatin receptor signaling.

Authors:  Anat Ben-Shlomo; Shlomo Melmed
Journal:  Trends Endocrinol Metab       Date:  2010-02-09       Impact factor: 12.015

2.  Mifepristone effects on tumor somatostatin receptor expression in two patients with Cushing's syndrome due to ectopic adrenocorticotropin secretion.

Authors:  C de Bruin; L J Hofland; L K Nieman; P M van Koetsveld; A M Waaijers; D M Sprij-Mooij; M van Essen; S W J Lamberts; W W de Herder; R A Feelders
Journal:  J Clin Endocrinol Metab       Date:  2011-11-16       Impact factor: 5.958

3.  Prolactinomas, Cushing's disease and acromegaly: debating the role of medical therapy for secretory pituitary adenomas.

Authors:  Beverly Mk Biller; Annamaria Colao; Stephan Petersenn; Vivien S Bonert; Marco Boscaro
Journal:  BMC Endocr Disord       Date:  2010-05-17       Impact factor: 2.763

Review 4.  Somatostatin and somatostatin receptor physiology.

Authors:  Philip Barnett
Journal:  Endocrine       Date:  2003-04       Impact factor: 3.633

Review 5.  Two types of ectopic Cushing syndrome or a continuum? Review.

Authors:  Marta Araujo Castro; Mónica Marazuela Azpiroz
Journal:  Pituitary       Date:  2018-10       Impact factor: 4.107

Review 6.  Medical management of Cushing's disease: what is the future?

Authors:  Maria Fleseriu; Stephan Petersenn
Journal:  Pituitary       Date:  2012-09       Impact factor: 4.107

7.  Epidrug-induced upregulation of functional somatostatin type 2 receptors in human pancreatic neuroendocrine tumor cells.

Authors:  Marije J Veenstra; Peter M van Koetsveld; Fadime Dogan; William E Farrell; Richard A Feelders; Steven W J Lamberts; Wouter W de Herder; Giovanni Vitale; Leo J Hofland
Journal:  Oncotarget       Date:  2016-05-19

8.  Association of SSTR2 polymorphisms and glucose homeostasis phenotypes: the Insulin Resistance Atherosclerosis Family Study.

Authors:  Beth S Sutton; Nicholette D Palmer; Carl D Langefeld; Bingzhong Xue; Alexandria Proctor; Julie T Ziegler; Steven M Haffner; Jill M Norris; Donald W Bowden
Journal:  Diabetes       Date:  2009-03-26       Impact factor: 9.461

Review 9.  Epigenetic regulation of somatostatin and somatostatin receptors in neuroendocrine tumors and other types of cancer.

Authors:  M J Klomp; S U Dalm; M de Jong; R A Feelders; J Hofland; L J Hofland
Journal:  Rev Endocr Metab Disord       Date:  2020-10-21       Impact factor: 9.306

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.